Literature DB >> 12579492

[Identification of a novel mutation IVS2-2A-->C of SEDL gene in a Chinese family with X-linked spondyloepiphyseal dysplasia tarda].

Chao Gao1, Qiang Luo, Huai-li Wang, Xiao-qun Gao, Qing-tang Fan, Hua Wang, Guang-yao Sheng, Jian-hua Zhou, Tie-zheng Gao.   

Abstract

OBJECTIVE: To identify the mutation of spondyloepiphyseal dysplasia tarda (SEDL) gene in a large Chinese family with X-linked spondyloepiphyseal dysplasia tarda and to make a discussion on the pathogenesis of SEDL at the molecular level.
METHODS: In two patients, four exons comprising the SEDL open reading frame as well as their exon/intron boundaries were analyzed by bi-directional direct sequencing of PCR products. The sequencing results were compared against the normal sequences in GenBank to find the mutation. Then the mutation was identified in other members of the family.
RESULTS: A nucleotide substitution of the splice acceptor in SEDL intron 2, IVS2 -2A-->C,was detected in two affected individuals (IV(15) V(3)) in the Chinese family with SEDL, but no sequence change occurring on exons 3-6 was detected. The transversion was also identified in four heterozygous carriers. The mutation was not found in two unaffected male individuals and fifteen normal controls. Furthermore, four potential carriers were identified in the family.
CONCLUSION: The mutation IVS2 -2A-->C of SEDL gene was firstly determined in the world. The change of the splice acceptor in SEDL intron 2 may cause skipping of exon 3 which is responsible for the disease. Molecular diagnosis can be made by detecting the mutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579492

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  1 in total

1.  A novel deletion variant in TRAPPC2 causes spondyloepiphyseal dysplasia tarda in a five-generation Chinese family.

Authors:  Cai Zhang; Caiqi Du; Juan Ye; Feng Ye; Renfa Wang; Xiaoping Luo; Yan Liang
Journal:  BMC Med Genet       Date:  2020-05-29       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.